Regarding HER-2 positive tumors, the single-arm, open-label phase II Fighter trial is currently evaluating the safety and activity of pemigatinib in HER-2 metastatic GC patients who progressed after a first-line treatment, including trastuzumab (EudraCT Number 2017-004522-14). This evidence concerns the gene ERBB2 and gastric cancer.